Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
26.40    -0.10 (-0.38%)
Bid:
26.50
Ask:
26.90
Spread: 0.40 (1.509%)
Market Cap: £113.65m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Update

20 Mar 2017 07:00

RNS Number : 8764Z
EKF Diagnostics Holdings PLC
20 March 2017
 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

EKF Diagnostics Holdings plc

("EKF", the "Company")

 

Update

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces the following update for shareholders.

 

The Directors are currently evaluating plans under which they would split the Company into two separate companies based on the business divisions, namely Point of Care and Lab Diagnostics. Whilst both these business divisions are valuable in their own right, the Directors consider that separating the companies out represents a better route for shareholders and one under which they are more likely to achieve a fair reflection of the value of each separate business.

 

However, based on tax advice received by the Company, it is the Directors' understanding that US federal income tax chargeable on any gain associated with the divestiture of the business could be significant. In order to mitigate these potentially adverse tax effects, the distribution needs to qualify as a 'tax-free spinoff'. There are numerous requirements in order to achieve this treatment, including that no acquisition of 50% or more of the shares in either the Company (i.e. the business that remains following the divestiture) or the newly separated company may take place within two years of the separation. Accordingly, the articles of association of the two separate companies would be amended so as to include a prohibition of the sale of 50% or more of the shares in the companies without the consent of their directors.

 

The implementation of the above proposal is envisaged to include a cancellation of the Company's shares from trading on AIM following which it is the Directors current intention to seek a listing of the shares of both companies on a market to be determined.

 

The Directors are sympathetic to individual investors' requirements and therefore in order to provide those shareholders that do not wish to wait for the completion of the restructuring and subsequent potential sale of the two businesses with an exit, the Company is evaluating the possibility of a share buyback offer to shareholders. This share buyback offer would, if completed, be prior to the commencement of the separation and would be at a price of 21.5p per share.

 

There can of course be no guarantee that the above proposals, including any share buyback, will be capable of being completed in the manner currently anticipated. Further announcements will be made at the appropriate time

 

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Christopher Mills, Non-Executive Chairman

Tel: 029 2071 0570

Julian Baines, CEO 

Richard Evans, FD & COO

N+1 Singer (Nomad & Broker)

Tel: 020 7496 3000

Alex Price / Shaun Dobson

Walbrook PR Limited

Tel: 020 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDGCGDXRXBBGRC
Date   Source Headline
24th Nov 202511:47 amRNSShare Buyback
19th Nov 20253:41 pmRNSShare Buyback
17th Nov 20252:12 pmRNSShare Buyback
4th Nov 20251:54 pmRNSTotal Voting Rights
3rd Nov 202510:19 amRNSShare Buyback
31st Oct 20251:02 pmRNSShare Buyback
30th Oct 202512:55 pmRNSShare Buyback
29th Oct 202510:59 amRNSShare Buyback
28th Oct 202511:00 amRNSShare Buyback
27th Oct 202510:25 amRNSShare Buyback
24th Oct 202511:10 amRNSShare Buyback
23rd Oct 202510:10 amRNSShare Buyback
21st Oct 20253:10 pmRNSShare Buyback & Extension of Buyback Programme
20th Oct 202512:24 pmRNSShare Buyback (Replacement)
20th Oct 202511:36 amRNSShare Buyback
17th Oct 20257:00 amRNSShare Buyback
15th Oct 202512:30 pmRNSShare Buyback
19th Sep 20254:25 pmRNSHolding(s) in Company
16th Sep 20257:15 amRNSLong Term Incentive Plan
16th Sep 20257:00 amRNSHalf-year Report
10th Sep 20257:00 amRNSNotice of interim results
26th Aug 20257:00 amRNSHematology contracts signed worth EUR 4.65m
28th Jul 20257:00 amRNSH1 2025 Trading Update
25th Jun 202512:00 pmRNSCancellation of Treasury Shares & TVR
17th Jun 20255:24 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSTotal Voting Rights
21st May 20257:00 amRNSAdditional Share Buyback Programme
20th May 20252:41 pmRNSResult of AGM and Voting Results
20th May 20257:00 amRNSAGM Statement
13th May 20257:00 amRNSShare Buyback & Completion of Share Buyback Prog.
9th May 20251:42 pmRNSShare Buyback
8th May 20259:11 amRNSShare Buyback
6th May 20253:55 pmRNSShare Buyback
29th Apr 20257:00 amRNSShare Buyback
28th Apr 20257:00 amRNSPosting of AR&A & Notice of AGM
9th Apr 20257:00 amRNSShare Buyback
8th Apr 20257:00 amRNSShare Buyback
7th Apr 20252:58 pmRNSShare Buyback
7th Apr 20257:00 amRNSShare Buyback
2nd Apr 20257:00 amRNSShare Buyback
1st Apr 20257:00 amRNSShare Buyback
26th Mar 20257:00 amRNSDirector/PDMR Shareholding
25th Mar 20257:00 amRNSAppointment of CEO
25th Mar 20257:00 amRNSFull year results
6th Mar 20257:00 amRNSNotice of Results & Investor Presentations
7th Feb 20253:04 pmRNSHolding(s) in Company
6th Feb 202511:34 amRNSHolding(s) in Company
29th Jan 20257:00 amRNSFY 2024 Trading Update
17th Sep 20247:00 amRNSHalf-year Report
3rd Sep 20247:00 amRNSNotice of Results and Investor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.